FindTrial
Sign In

Comparison of Vortioxetine and Escitalopram, in Adults with Depression

Vortioxetine versus Escitalopram in Major Depressive Disorder A Comparative Study of Efficacy, Safety, Functional Improvement and Quality of Life - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090799
Enrollment
100
Registered
2025-07-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate

Interventions

Intervention1: VORTIOXETINE: 20mg/day, per oral , for a total duration of 24 weeks Control Intervention1: ESCITALOPRAM: 20mg/day per oral for a total duration of 24 weeks

Sponsors

DR GARIMA GUPTA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Adults aged 18-55 years diagnosed with moderate major depressive disorder based on DSM-5 criteria. 2) Patients with a Hamilton Depression Rating Scale score between 14-22 indicating moderate depression. 3) Those who have not used antidepressants in the past three months. 4) Those patients or caregivers who are willing to give written infomred consent form.

Exclusion criteria

Exclusion criteria: 1) Who have not previously experienced hypersensitivity or contraindication to vortioxetine or escitalopram 2)Clinical situation requiring alternative drugs or intervention. 3)Drugs which are CYP3A4/2D6 and CYP2C19 inhibitors and inducers ( Concomitant medication) 4)Any co-morbid neurological or mental disorder. 5)Any serious medical/surgical illness. 6)Established treatment resistance to antidepressants 7)History of drug or alcohol abuse in the last six months.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of vortioxetine and escitalopram in improving depressive symptoms in patients with moderate to major depressive disorder, using standardized rating scales over a 24-week treatment period.Timepoint: baseline, 8, 16 and 24 weeks—

Secondary

MeasureTime frame
To evaluate the safety & tolerability of vortioxetine & escitalopram by assessing adverse events & dropout rates during the treatment course. To assess functional improvement in patients receiving either vortioxetine or escitalopram using tools like the Sheehan Disability Scale (SDS). To compare quality of life outcomes using validated questionnaires between the two treatment groups. Timepoint: 0,8,16,24 weeks—

Countries

India

Contacts

Public ContactDR GARIMA GUPTA

SANTOSH MEDICAL COLLEGE, SDTU

drsajidrana@gmail.com9810849797

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026